Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Mesoglycan→

Mesoglycan Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
Not available
Molecular formula
Not available
Molecular weight
Not available
Drug class
Glycosaminoglycan mixtureantithrombotic and venotonic agent
Mechanism of action
A natural glycosaminoglycan preparation containing heparan sulfate, dermatan sulfate, slow-moving heparin and chondroitin sulfate. It has reported anticoagulant, antithrombotic, endothelial-protective and wound-healing activity; mechanisms include modulation of coagulation and vascular smooth-muscle signalling.
Indications / reported uses
  • Used in some countries for chronic venous disease and selected vascular disorders; topical mesoglycan/hyaluronic-acid medical devices are also used in wound management. Clinical use and authorisation are product- and jurisdiction-specific.

Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10995001/ · https://pubmed.ncbi.nlm.nih.gov/?term=mesoglycan+chronic+venous+disease · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Mesoglycan Environmental Risk Assessment (ERA) (the Mesoglycan ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.